Odyssey Health, Inc. (ODYY) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerOdyssey Health, Inc. (ODYY) trades at $0.0065. Odyssey Health, Inc. is a medical company focused on developing and acquiring medical products and health-related technologies. Their portfolio includes devices for heart monitoring, choking rescue, and concussion treatment. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for ODYY: ODYY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Odyssey Health, Inc. (ODYY) Healthcare & Pipeline Overview
Odyssey Health, Inc. develops and acquires medical devices, including CardioMap for heart monitoring, Save A Life for choking rescue, and ONP-002 for mild brain trauma. The company operates within the competitive medical device sector, focusing on innovative solutions for unmet healthcare needs.
What Is the Investment Thesis for ODYY?
Odyssey Health, Inc. presents a speculative investment opportunity within the medical device sector. The company's focus on developing and acquiring medical products and health-related technologies, including CardioMap, Save A Life, and ONP-002, could drive future growth if these products gain regulatory approval and market acceptance. However, the company's small market capitalization of $0.01 billion and negative beta of -1.08 indicate high volatility and sensitivity to market conditions. The absence of a dividend reflects a focus on reinvesting earnings into research and development. Successful commercialization of ONP-002 for concussion treatment represents a significant potential catalyst, but clinical trial outcomes and regulatory hurdles pose substantial risks. Investors should carefully consider the company's limited financial resources and competitive landscape before investing.
Based on FMP financials and quantitative analysis
ODYY Key Highlights
Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
- Development of CardioMap heart monitoring device aims to address a significant market need for early cardiac abnormality detection.
- ONP-002, a treatment for mild brain trauma or concussion, represents a potential breakthrough in neurological health.
- The company's focus on acquiring and developing medical technologies could lead to strategic partnerships or acquisitions.
- Incorporated in 2014, Odyssey Health is still in its early stages of development, offering potential for long-term growth.
Who Are ODYY's Competitors?
ODYY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AEMD Aethlon Medical, Inc. | $4.84 | -5.28% | $7.78M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $2.38 | -0.21% | $36.2M | 39 5-pillar |
| LNSR LENSAR, Inc. | $4.85 | -1.22% | $59.6M | 44 5-pillar |
| HSDT Solana Company | $1.66 | +1.84% | $104M | 43 5-pillar |
| APYX Apyx Medical Corporation | $2.49 | -2.54% | $105M | 33 5-pillar |
| OWLT Owlet, Inc. | $3.67 | +12.92% | $110M | 41 5-pillar |
| INGN Inogen, Inc. | $5.42 | -2.69% | $141M | 37 5-pillar |
| ANIK Anika Therapeutics, Inc. | $13.28 | -2.50% | $178M | 71 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ODYY's Key Strengths?
Innovative product pipeline with potential for significant market impact.
- Focus on addressing unmet needs in the healthcare sector.
- Proprietary technology and patents protecting key products.
- Experienced management team with expertise in medical device development.
What Are ODYY's Weaknesses?
Limited financial resources and small market capitalization.
- Dependence on successful clinical trials and regulatory approvals.
- Lack of established sales and marketing infrastructure.
- High concentration of risk in a few key products.
What Are the Key Risks for ODYY?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approval for ONP-002.
- Competition from established medical device companies.
- Product liability risks and potential recalls.
- Limited financial resources and dependence on external funding.
- Changes in healthcare reimbursement policies.
What Are ODYY's Competitive Advantages?
- Proprietary technology in CardioMap heart monitoring device.
- Patents protecting Save A Life choking rescue devices.
- Potential market exclusivity for ONP-002 concussion treatment.
- First-mover advantage in specific niche markets.
What Does ODYY Do?
Odyssey Health, Inc., incorporated in 2014 and based in Las Vegas, Nevada, is a medical company dedicated to the development and acquisition of innovative medical products and health-related technologies. The company's mission is to address unmet needs in the healthcare sector through the creation and commercialization of cutting-edge medical devices. Odyssey Health's portfolio includes CardioMap, a heart monitoring and screening device designed to provide early detection of cardiac abnormalities. Additionally, they offer Save A Life, a suite of choking rescue devices aimed at preventing asphyxiation. A key product candidate in their pipeline is ONP-002, a treatment for mild brain trauma or concussion, representing a significant focus on neurological health. Formerly known as Odyssey Group International, Inc., the company has evolved to concentrate on medical solutions, seeking to improve patient outcomes and quality of life through technological advancements in healthcare.
What Products and Services Does ODYY Offer?
- Develops CardioMap, a heart monitoring and screening device.
- Creates Save A Life choking rescue devices.
- Focuses on ONP-002 for the treatment of mild brain trauma or concussion.
- Acquires medical products and health-related technologies.
- Aims to improve patient outcomes through innovative medical solutions.
- Seeks to address unmet needs in the healthcare sector.
How Does ODYY Make Money?
- Develops and patents medical device technologies.
- Seeks regulatory approvals for its products.
- Commercializes its products through direct sales, partnerships, and distribution agreements.
- Acquires existing medical device companies and technologies to expand its portfolio.
What Industry Does ODYY Operate In?
Odyssey Health, Inc. operates within the medical device industry, a sector characterized by rapid innovation and stringent regulatory requirements. The global medical device market is projected to reach $600 billion by 2026, driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. Competition is intense, with established players like Medtronic and Johnson & Johnson, as well as numerous smaller companies vying for market share. Odyssey Health's success depends on its ability to develop and commercialize innovative products that address unmet clinical needs and navigate the complex regulatory landscape.
Who Are ODYY's Key Customers?
- Hospitals and clinics that use CardioMap for heart monitoring.
- Emergency medical service providers who utilize Save A Life choking rescue devices.
- Patients who suffer from mild brain trauma or concussion and may benefit from ONP-002.
- Consumers purchasing choking rescue devices for home use.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Odyssey Health, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Odyssey Health, Inc. stands at 57.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Odyssey Health, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Joseph Michael Redmond. ODYY has traded publicly since 2021.
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 7 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
ODYY Latest News
-
Odyssey Health, Inc. (OTCMKTS:ODYY) Sees Significant Decline in Short Interest
defenseworld.net · Nov 2, 2026
ODYY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ODYY.
Price Targets
Wall Street price target analysis for ODYY.
ODYY MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ODYY; grades run from A+ (80-100) to F (below 30).
ODYY OTC Market Information
ODYY trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Odyssey Health, Inc. Healthcare Stock: Key Questions Answered
What is Odyssey Health, Inc.'s drug pipeline status?
Odyssey Health, Inc.'s primary drug candidate is ONP-002, which is being developed for the treatment of mild brain trauma or concussion.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- The company's future performance is subject to various risks and uncertainties.